Continue losartan but investigate and address reversible causes of eGFR decline immediately
After 20 years on losartan, a declining eGFR requires careful evaluation rather than automatic discontinuation. The evidence strongly supports continuing ARB therapy even with declining kidney function, as discontinuation is associated with increased mortality and cardiovascular events 1. However, you must systematically rule out acute, reversible causes of worsening renal function.
Immediate Assessment Required
Check the following within the next 1-2 weeks:
- Volume status: Assess for dehydration, overdiuresis, or recent diarrhea/vomiting
- Blood pressure: Look for hypotension (MAP <65 mmHg) or recent aggressive BP lowering
- Serum potassium: Monitor for hyperkalemia
- Medication review: Identify NSAIDs, cyclosporine, or other nephrotoxins
- Renal artery stenosis: Consider if eGFR dropped >30% acutely or if bilateral disease suspected
Understanding the Expected eGFR Pattern
An initial 10-20% decline in eGFR after starting ARBs is expected and beneficial 2. This represents reversal of glomerular hyperfiltration through efferent arteriolar vasodilation—the mechanism by which these drugs protect kidneys long-term. This hemodynamic change is transient and not indicative of structural kidney damage 3.
However, after 20 years of therapy, you're likely past this initial phase. The key question is: What is the rate and pattern of your current decline?
When to Continue Losartan
Continue losartan if:
- eGFR decline is <30% from your stable baseline 4
- No acute precipitating factors identified (volume depletion, hypotension, nephrotoxins)
- Potassium remains manageable (<5.5 mEq/L with interventions)
- Blood pressure is controlled without symptomatic hypotension
The evidence is compelling: In a propensity-matched study of 2,410 patients with eGFR <30 mL/min/1.73m², continuing ARB therapy reduced mortality (HR 0.72) and major cardiovascular events (HR 0.73) compared to discontinuation, without increasing end-stage kidney disease risk 1. Even patients who experienced eGFR drops after ARB initiation had better long-term outcomes when therapy was continued 5.
When to Temporarily Hold or Reduce Losartan
Hold or reduce losartan if:
- eGFR dropped >30% within 4 weeks of any dose change 4
- Symptomatic hypotension despite volume optimization
- Uncontrolled hyperkalemia (>5.5-6.0 mEq/L) despite potassium-lowering measures
- Acute kidney injury from volume depletion, sepsis, or contrast exposure 2
- eGFR approaching dialysis threshold (<15 mL/min/1.73m²) with uremic symptoms 4
Critical Pitfalls to Avoid
Do not discontinue losartan solely based on declining eGFR numbers. The 2001 AHA guidelines explicitly state: "there is no serum creatinine level per se for which use of ACE inhibitor [or ARB] therapy is contraindicated" 2. The same principle applies after decades of use.
Do not combine losartan with ACE inhibitors or direct renin inhibitors. The VA NEPHRON-D trial definitively showed that dual RAS blockade (losartan + lisinopril) increased acute kidney injury and hyperkalemia without additional benefit 6. This combination is contraindicated 4.
Do not assume all eGFR decline is from the medication. After 20 years, you may have developed:
- Progressive diabetic nephropathy (if diabetic)
- Renal artery stenosis
- Volume depletion from diuretics
- Concurrent NSAID use
- Age-related nephrosclerosis (normal decline is 1 mL/min/1.73m²/year; heart failure patients average 2-3 mL/min/1.73m²/year) 3
Monitoring Strategy
Check labs 2-4 weeks after any intervention 4:
- Serum creatinine and eGFR
- Serum potassium
- Blood pressure
If hyperkalemia develops, manage it medically (dietary restriction, diuretics, potassium binders) rather than stopping losartan 2, 4. Only 6.4% of patients in major trials developed potassium >5.5 mEq/L 2.
Long-term Perspective
Research shows that patients with larger initial eGFR drops after starting ARBs actually have slower long-term eGFR decline 5. This paradox reflects the drug's renoprotective mechanism. After the initial hemodynamic adjustment, the slope of decline typically parallels or improves compared to untreated patients 3.
The 2020 European Heart Failure Association position statement emphasizes that the initial eGFR dip is a hemodynamic feature, not structural damage, and the long-term slope benefit justifies continuation 3.
Bottom Line Algorithm
- Measure current eGFR decline rate: Calculate annual change over past 1-2 years
- If >5 mL/min/1.73m²/year: Investigate reversible causes aggressively
- If acute drop >30%: Hold losartan temporarily, correct precipitants, then restart 2, 4
- If gradual decline <30% with stable potassium: Continue losartan and optimize other risk factors (BP control, glycemic control if diabetic, avoid nephrotoxins)
- Consider nephrology referral if eGFR <30 mL/min/1.73m² or decline remains unexplained 7
The FDA label confirms that renal function deterioration with losartan typically reverses with volume repletion or removal of precipitants 6. Discontinuation should be temporary and targeted at correctable causes, not permanent based on eGFR alone.